Valneva Shares Fall Below Its Support at €2.76 with an Oversold RSI
Shares of the Nantes-based vaccine specialist fell by 3.4% this Thursday to €2.726, in a Parisian market significantly trending downward. This drop extends a negative sequence that has seen the share price lose more than a quarter of its value in three months, while the CAC 40 is down 1.25% during the session.
Valneva's Share Price Now Significantly Below Key Moving Averages
Valneva's share price is now significantly below its main moving averages: the 50-day moving average is at €4.18 and the 200-day at €3.88, marking significant gaps from the current price. This pronounced detachment reflects a bearish trend established over several weeks. The RSI, at 27, signals an oversold zone, indicating that selling pressure overwhelmingly dominates the trading without a technical rebound currently in sight. Over the past seven days, the decline reached 4.22%, and the performance over one year stands at -14.81%. The proximity of the technical support identified at €2.76 was a point of focus: the share price has fallen below this level during the session, to €2.726. If this break is confirmed at the close, it could pave the way for a continuation of the movement towards the lower Bollinger band, located at €2.05. The major resistance, positioned at €5.08, appears very distant from current levels.
Thursday's Session Reflects a Tense Stock Market Environment
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Thursday's session occurs in a tense stock market environment. The CAC 40 is down 1.25% during the session, while the SBF 120 loses 1.26%. Healthcare stocks are not spared: Sanofi is down 0.74% and UCB falls by 3.14%, illustrating sectoral pressure on the day. Valneva's negative beta (-0.15) historically indicates a weak correlation with market movements, suggesting that factors specific to the stock weigh more heavily than the overall context on the recent price evolution. The one-month volatility, measured at 23.16%, remains high and reflects the amplitude of oscillations observed in recent weeks. The next key dates for shareholders are set for May 7, 2026, with the publication of the first quarter results, followed by the annual general meeting scheduled for June 1. These milestones will be important for assessing the financial trajectory of the group specialized in developing vaccines against infectious diseases.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
